Loading...
XMAD
ALM
Market cap2.15bUSD
Apr 08, Last price  
9.18EUR
1D
1.89%
1Q
11.54%
Jan 2017
-36.45%
IPO
-37.47%
Name

Almirall SA

Chart & Performance

D1W1MN
No data to show
P/E
193.13
P/S
1.99
EPS
0.05
Div Yield, %
2.00%
Shrs. gr., 5y
2.39%
Rev. gr., 5y
2.88%
Revenues
986m
+10.20%
736,132,000792,542,000853,084,000902,800,000925,500,000882,400,000768,418,000715,232,000747,628,000819,040,000689,225,000764,361,000639,381,000756,934,000855,339,0001,614,854,000827,195,000863,248,000894,516,000985,721,000
Net income
10m
P
117,725,000147,250,000131,206,000136,100,000151,500,000118,600,00084,166,00076,291,000-33,717,000448,429,000131,826,00075,479,000-303,961,00077,674,000105,909,00074,280,000-40,859,0004,281,000-38,474,00010,147,000
CFO
161m
+71.97%
141,570,000164,089,000179,031,000233,100,000261,600,000174,600,000100,140,000112,754,00067,114,000646,935,000170,884,000105,056,0006,094,000143,209,000276,146,000164,764,000233,852,000155,102,00093,485,000160,767,000
Dividend
May 17, 20240.184 EUR/sh
Earnings
May 09, 2025

Profile

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
URL
https://www.almirall.es/
IPO date
Apr 19, 2007
Employees
1,876
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
985,721
10.20%
894,516
3.62%
863,248
4.36%
Cost of revenue
428,620
503,450
289,175
Unusual Expense (Income)
NOPBT
557,101
391,066
574,073
NOPBT Margin
56.52%
43.72%
66.50%
Operating Taxes
16,351
21,283
26,746
Tax Rate
2.94%
5.44%
4.66%
NOPAT
540,750
369,783
547,327
Net income
10,147
-126.37%
(38,474)
-998.72%
4,281
-110.48%
Dividends
(3,288)
(2,592)
(12,419)
Dividend yield
0.19%
0.16%
0.76%
Proceeds from repurchase of equity
539
197,924
BB yield
-0.03%
-11.92%
Debt
Debt current
18,182
17,210
16,714
Long-term debt
435,211
429,847
426,197
Deferred revenue
4,485
Other long-term liabilities
94,751
102,554
89,947
Net debt
59,946
36,089
159,433
Cash flow
Cash from operating activities
160,767
93,485
155,102
CAPEX
(29,835)
(33,499)
(116,480)
Cash from investing activities
(140,040)
(122,559)
(68,543)
Cash from financing activities
(31,584)
168,205
(45,122)
FCF
486,492
368,429
505,413
Balance
Cash
377,298
388,090
248,823
Long term investments
16,149
22,878
34,655
Excess cash
344,161
366,242
240,316
Stockholders' equity
35,763
920,392
1,008,233
Invested Capital
1,960,666
1,602,958
1,545,579
ROIC
30.35%
23.49%
35.51%
ROCE
27.03%
19.16%
30.81%
EV
Common stock shares outstanding
211,437
196,992
180,758
Price
8.24
-2.25%
8.43
-6.75%
9.04
-20.00%
Market cap
1,742,241
4.91%
1,660,643
1.63%
1,634,052
-19.17%
EV
1,802,187
1,696,732
1,793,485
EBITDA
696,185
515,382
694,709
EV/EBITDA
2.59
3.29
2.58
Interest
8,219
15,388
7,439
Interest/NOPBT
1.48%
3.93%
1.30%